The cord blood banking market is an interesting market, as its rate of growth has slowed over the past couple years. When the market is assessed by the number of cord blood units stored, cord tissue units banked, and number of units transplanted, there are regions that are experiencing growth and regions in decline. In particular, cord blood markets are experiencing strong growth within Asia, are relatively flat within North America, and are in decline within Europe. Additionally, cord blood banks within Europe have been some of the most proactive banks to expand into other areas of stem cell storage. [Read more…]
Texas Stem Cell Partners with Cesca Therapeutics to Use AutoXpress® Technology
Located in Rancho Cordova, California, Cesca Therapeutics specializes in the research, development, and commercialization of autologous cell-based therapeutics for regenerative medicine applications. With the stem cell and cord blood marketplace, the company is best known for it automated blood and bone marrow processing systems, such as the AutoXpress® Platform (AXP®), the MarrowXpress® Platform, the BioArchive® System, and others.
Already a dominant player with the cord blood banking markets, Cesca Therapeutics continues its dominance with today’s announcement that the Texas Stem Cell has entered into an agreement to use Cesca’s AutoXpress technology.
Located in Houston, Texas Stem Cell is a stem cell bank that offer the storage of newborn umbilical cord blood, cord tissue, and placenta. As a “hybrid” bank, it offers both private (fee-based) storage and public (free) donation of stem cell samples.
In news released today, the companies announced:
“Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Texas Stem Cell has committed to utilizing Cesca’s AutoXpress® AXP technology for its cord blood banking business. The AXP platform includes a ‘smart’ processing device and sterile disposable that automatically concentrates the stem cells from a cord blood unit in less than one hour and delivers them directly into Cesca’s patented sample bag which is optimized for cryopreservation and storage.
Cesca’s AXP technology is widely used in cord blood banks around the world and has been referenced in dozens of clinical publications. Recently, clinical focus on cord blood has expanded due to the emergence of protocols enabling the expansion of cord blood cells in vitro, for subsequent therapeutic use in treatments for many forms of blood cancers including leukemia and lymphomas.”
To learn more about the agreement, see the company press release from Cesca Therapeutics.
About BioInformant
As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.
We Interviewed Key Stem Cell Industry Leaders (Here’s What We Learned)
In groundbreaking news released January 2016, the Tisch MS Research Center of New York (MSRCNY) announced it is pursuing a Phase II clinical trial exploring spinal injections of neural progenitors derived from bone marrow mesenchymal stem cells (MSC-NPs) for the treatment of multiple sclerosis (MS).
Importantly, the Phase I trial was the first time in history that a treatment demonstrated reversal of established disability in MS patients. Therefore, we are excited to release an exclusive interview with Dr. Saud Sadiq, Chief Research Scientist for Tisch MSRCNY. [Read more…]
Cesca Therapeutics Acquires $15M Strategic Investment From Chinese Cloning Giant, Boyalife Group
On February 3, 2016, Cesca Therapeutics (NASDAQ:KOOL) released news that Boyalife Group was making a $15 million strategic investment in the company.
Stock priced jumped following the news, although it has since been volatile.
Located in Rancho Cordova, California, Cesca Therapeutics specializes in the research, development, and commercialization of autologous cell-based therapeutics for regenerative medicine applications. With the stem cell and cord blood marketplace, the company is best known for it automated blood and bone marrow processing systems, such as the AutoXpress® Platform (AXP®), the MarrowXpress® Platform, the BioArchive® System, and others.
On the other hand, Boyalife Group is best known for its cloning technologies, although it describes itself as involved with “stem cell technologies, regenerative medicine, genomics and cloning, cancer immune therapies, disease mechanistic studies and innovative drug discovery.”
As stated in the press release:
“Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that affiliates of Boyalife Group have agreed to invest $15.0 million in the Company (the “Boyalife Financing”), enabling the Company to repay currently outstanding senior secured convertible debentures and retire associated Series B Warrants. The investments will also provide additional working capital to fund the Company’s ongoing operations and strategic initiatives.”
Additionally, Dr. Xiaochun Xu, Chairman and CEO of Boyalife Group commented:
“This investment lays the foundation for what we see as a strong and continuing strategic alliance between our two companies. Beyond Cesca’s existing pipeline of autologous cell-based therapies, this partnership has the potential to enable access to a much broader scope of clinical applications as well as accelerate penetration of the 1.3 billion person market in China.”
To learn more, visit www.CescaTherapeutics.com.
About BioInformant
BioInformant is the only research firm to serve the stem cell sector since it emerged. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson, BioInformant is your global leader in stem cell industry data.
Click here to view our global strategic reports for the stem cell industry.